• Je něco špatně v tomto záznamu ?

Assessing the status of European laboratories in evaluating biomarkers for chronic kidney diseases (CKD) and recommendations for improvement: insights from the 2022 EFLM Task Group on CKD survey

E. Cavalier, K. Makris, O. Portakal, A. Nikler, P. Datta, T. Zima, P. Delanaye, EFLM Task Group on CKD

. 2024 ; 62 (2) : 253-261. [pub] 20231002

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24000073

OBJECTIVES: Chronic kidney disease (CKD) is a global health issue, ranking as the third leading cause of death worldwide. CKD diagnosis and management depend on clinical laboratory tests, necessitating consistency for precise patient care. Global harmonization of CKD testing through clinical practice guidelines (CPGs) is recommended. Prior to CPG development, assessing the current CKD testing landscape is crucial. In 2022, the European Federation of Laboratory Medicine (EFLM) conducted an online survey among European laboratories associated with EFLM, evaluating CKD testing practices, including new glomerular filtration rate (GFR) estimation methods. This report summarizes the 2022 survey findings and offers recommendations for improving CKD test standardization. METHODS: An online survey was conducted in November 2022 using a questionnaire hosted on LimeSurvey sent to European laboratories affiliated with the EFLM. The survey results were recorded in Excel files and analysed. RESULTS: The results highlight significant discrepancies among countries in unit expression, methods, cystatin C use, and GFR calculation equations. Additionally, limited attention to pediatric renal biology specifics, varied proteinuria and albuminuria result expressions, and limited awareness of GFR measurement methods through iohexol clearance are noted. CONCLUSIONS: In an effort to enhance the standardization of crucial biomarkers utilized in nephrology for evaluating renal function and diagnosing kidney injuries, the EFLM Task Group on CKD suggests nine practical recommendations tailored for European laboratories. The group is confident that implementing these measures will minimize result expression discrepancies, ultimately leading to enhanced patient care.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000073
003      
CZ-PrNML
005      
20240213092944.0
007      
ta
008      
240109s2024 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1515/cclm-2023-0987 $2 doi
035    __
$a (PubMed)37773773
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Cavalier, Etienne $u Department of Clinical Chemistry, University of Liege, CIRM, CHU de Liège, Liège, Belgium $1 https://orcid.org/0000000309472226
245    10
$a Assessing the status of European laboratories in evaluating biomarkers for chronic kidney diseases (CKD) and recommendations for improvement: insights from the 2022 EFLM Task Group on CKD survey / $c E. Cavalier, K. Makris, O. Portakal, A. Nikler, P. Datta, T. Zima, P. Delanaye, EFLM Task Group on CKD
520    9_
$a OBJECTIVES: Chronic kidney disease (CKD) is a global health issue, ranking as the third leading cause of death worldwide. CKD diagnosis and management depend on clinical laboratory tests, necessitating consistency for precise patient care. Global harmonization of CKD testing through clinical practice guidelines (CPGs) is recommended. Prior to CPG development, assessing the current CKD testing landscape is crucial. In 2022, the European Federation of Laboratory Medicine (EFLM) conducted an online survey among European laboratories associated with EFLM, evaluating CKD testing practices, including new glomerular filtration rate (GFR) estimation methods. This report summarizes the 2022 survey findings and offers recommendations for improving CKD test standardization. METHODS: An online survey was conducted in November 2022 using a questionnaire hosted on LimeSurvey sent to European laboratories affiliated with the EFLM. The survey results were recorded in Excel files and analysed. RESULTS: The results highlight significant discrepancies among countries in unit expression, methods, cystatin C use, and GFR calculation equations. Additionally, limited attention to pediatric renal biology specifics, varied proteinuria and albuminuria result expressions, and limited awareness of GFR measurement methods through iohexol clearance are noted. CONCLUSIONS: In an effort to enhance the standardization of crucial biomarkers utilized in nephrology for evaluating renal function and diagnosing kidney injuries, the EFLM Task Group on CKD suggests nine practical recommendations tailored for European laboratories. The group is confident that implementing these measures will minimize result expression discrepancies, ultimately leading to enhanced patient care.
650    _2
$a lidé $7 D006801
650    _2
$a dítě $7 D002648
650    12
$a laboratoře $7 D007753
650    _2
$a vyšetření funkce ledvin $x metody $7 D007677
650    _2
$a hodnoty glomerulární filtrace $7 D005919
650    _2
$a biologické markery $7 D015415
650    _2
$a průzkumy a dotazníky $7 D011795
650    12
$a chronická renální insuficience $x diagnóza $7 D051436
650    _2
$a kreatinin $x metabolismus $7 D003404
655    _2
$a časopisecké články $7 D016428
700    1_
$a Makris, Konstantinos $u Department of Clinical Biochemistry, KAT General Hospital, Athens, Greece
700    1_
$a Portakal, Oytun $u Department of Biochemistry, Hacettepe University Medical School, Ankara, Türkiye
700    1_
$a Nikler, Ana $u Department of Medical Laboratory Diagnostics, University Hospital "Sveti Duh", Zagreb, Croatia
700    1_
$a Datta, Pradip $u Siemens Healthineers Diagnostics, Newark, DE, USA
700    1_
$a Zima, Tomas $u Institute of Medical Chemistry and Laboratory Medicine, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
700    1_
$a Delanaye, Pierre $u Department of Nephrology, Dialysis and Hypertension, CHU de Liège, Liège, Belgium $1 https://orcid.org/0000000214805761
710    2_
$a EFLM Task Group on CKD
773    0_
$w MED00010886 $t Clinical chemistry and laboratory medicine $x 1437-4331 $g Roč. 62, č. 2 (2024), s. 253-261
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37773773 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213092941 $b ABA008
999    __
$a ok $b bmc $g 2049025 $s 1209767
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 62 $c 2 $d 253-261 $e 20231002 $i 1437-4331 $m Clinical chemistry and laboratory medicine $n Clin Chem Lab Med $x MED00010886
LZP    __
$a Pubmed-20240109
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace